08/06/09 Marco Island, Florida
Health care stocks are traditionally countercyclical. This isn’t surprising since consumers tend to cut back on everything else before sacrificing medical care. It’s no accident that biotechs in the Breakthrough Technology Report portfolio have done well.
There is, however, another aspect of companies that control breakthrough medical technologies that makes them immune to downturns: Their initial customers include extremely wealthy early adopters.
The number of high net-worth individuals — people controlling at least $1 million in assets excluding primary residence — has been growing dramatically for decades, far outpacing inflation. They and their immediate families comprise a population that may exceed 25 million people. Spending on luxury items by HNWIs and family members remains strong. While the biggest concentrations of HNWIs are still in North America and Europe, the fastest growth, by far, is in China and India.
The market segment that continues to buy Ferraris, yachts and private jets will also buy regenerative therapies for themselves and their loved ones. HNWIs are largely immune to the big economic fluctuations. When stem cell therapies bestow the power to rejuvenate hearts, livers, skin and cartilage, even at sky-high prices, there will be millions and millions of happy buyers.
The Daily Reckoning is your premier source for making sense of the news Washington and Wall Street generate. Each business day, The Daily Reckoning calls on its stable of world-class writers and thinkers to show you how to get ahead.
Start your 100% FREE subscription to The Daily Reckoning today and you’ll get a free research report, “How to Survive the Fall of Social Security.” Simply enter your email address below to get your free report and join over 495,000 worldwide Daily Reckoning subscribers!
We Respect Your Privacy and We will
Never Share or Sell Your Email Address





Right. And of course, there will be a transparent bourse on which this action will happen, managed by Golden Slacks.